Benefits
Verbal memory preservation in older adults
In 39 healthy older adults aged 60 to 78, an anserine plus carnosine combination at about 1 gram a day for 3 months preserved delayed-recall verbal memory compared with placebo (p=0.0128), while immediate recall showed no significant difference. The effect is specifically on memory consolidation (the ability to retrieve information after a delay) rather than short-term working memory. All of the trials come from one Japanese research group, are small, and test the combination rather than anserine on its own, so this has not been independently replicated. Reasonable consideration for older adults concerned about subjective memory decline; not validated as a memory enhancer in healthy younger adults.
Brain blood flow — particularly helpful for APOE4 carriers
In a sub-analysis of a 12-month trial in 68 people aged 65 and over, the anserine plus carnosine combination preserved blood flow in the prefrontal brain specifically in carriers of the APOE4 gene variant, and not in the group as a whole. That is a subgroup finding inside one small trial, so it is a preliminary signal rather than a demonstrated benefit, and it does not show that the supplement prevents or slows any disease. If you know your APOE4 status and are considering this, talk it over with your doctor.
Mild cognitive impairment — benefit specific to APOE4
This was studied in 54 people already diagnosed with mild cognitive impairment, who took the anserine plus carnosine combination for 12 weeks. One measure, the global Clinical Dementia Rating, improved compared with placebo (p=0.023), mainly in APOE4 carriers. Three other measures, the MMSE, the Wechsler Memory Scale and the ADAS, showed no significant change. A supplement is not a treatment for mild cognitive impairment, and a result in diagnosed patients does not tell you what it would do for a healthy adult. Honest framing: this is preliminary, genotype-stratified evidence rather than broad cognitive benefit. Most relevant when APOE4 status is known and MCI is documented.
Reduces inflammatory signaling
In a trial in 60 healthy older adults, 3 months of the anserine plus carnosine combination lowered expression of one inflammatory chemokine, CCL24, in white blood cells. The link to memory came from a correlation seen only in the participants in their 70s, which is a small after-the-fact subgroup look and cannot show that one caused the other. This study is described on this page but is not among the references listed below. Mechanism is suggestive but not definitive — inflammatory marker changes are markers, not validated clinical outcomes. Best treated as supporting evidence for the cognitive applications rather than a standalone benefit.
Physical capacity: not supported by the cited studies
No study cited on this page measured BMI or physical fitness, so there is nothing here to support a physical performance or body composition claim for anserine. Don't choose anserine specifically for physical performance; for that purpose, beta-alanine (which produces muscle carnosine increases) or creatine have far stronger evidence.
Mechanism of action
Acid Buffering at Body pH
Anserine has higher buffering capacity than carnosine at physiological pH (7.4) due to the methyl group on histidine's imidazole ring. This is laboratory chemistry. No human trial cited here measured pH buffering in muscle or brain tissue, so it is a proposed mechanism rather than a measured effect in people.
Resistance to Carnosinase Breakdown
Carnosine is rapidly cleaved by serum carnosinase (CN1) in human blood, severely limiting bioavailability. Anserine is not broken down by human carnosinase, so more of it survives in the blood after an oral dose. No trial cited here compared anserine head to head with carnosine, and the products tested in the human studies contained both, so there is no evidence that one works better than the other.
Antioxidant and Anti-Glycation Activity
Anserine and carnosine scavenge reactive oxygen species and reactive carbonyl species (methylglyoxal, malondialdehyde) — preventing protein damage and AGE (advanced glycation endproduct) formation. This work comes from laboratory experiments. It has not been shown to produce a health effect in people, and it does not mean anserine treats or prevents diabetes or any other disease.
Neurovascular Unit Protection
Animal Alzheimer's-model studies (AβPP/PSEN1dE9 mice) showed anserine treatment recovered memory deficits, improved pericyte coverage on brain endothelial cells, and reduced chronic glial neuroinflammation. The proposed mechanism is protection of the neurovascular unit (endothelial cells, pericytes, glial cells). This is mouse data, not human evidence, and it is one possible explanation for the blood flow finding in people rather than a confirmed one.
Methylglyoxal Detoxification
Methylglyoxal is a reactive aldehyde that researchers study in connection with tissue and blood vessel damage. In laboratory tests anserine mops it up before it can react with proteins, which is the same chemistry behind its anti-glycation activity. None of this has been shown to produce a health benefit in people.
Clinical trials
Double-blind, randomized, placebo-controlled pilot trial in elderly volunteers. ACS group: 1.0 g anserine/carnosine (3:1 ratio) daily for 3 months. Outcomes: psychological tests including Wechsler Memory Scale-Logical Memory (WMS-LM). (Hisatsune, Kaneko, Kurashige, Cao, Satsu, Totsuka, Katakura, Imabayashi, J Alzheimers Dis)
39 healthy elderly volunteers aged 60-78 in Tokyo area.
Significant preservation of delayed-recall verbal episodic memory (WMS-LM2) in ACS group vs. placebo (p=0.0128). NO significant effect on immediate recall (WMS-LM1), suggesting effect is specifically on memory registration/consolidation rather than short-term working memory. This was a small pilot trial with 39 completers, it tested the combination rather than anserine alone, and it has not been repeated by an independent research group.
Sub-analysis of MRI data and cognitive test scores from a previously-reported clinical trial. 68 participants aged ≥65 received ACS (750 mg anserine + 250 mg carnosine) or placebo for 12 months. Arterial spin labeling (ASL) and diffusion tensor imaging (DTI) MRI plus WMS-LM. (Hisatsune, Yoshimine, Wakana, Tanaka, Asada, J Alzheimers Dis)
68 participants aged ≥65 stratified by APOE genotype.
ACS preserved prefrontal brain blood flow specifically in APOE4 carriers — a high-risk genotype for accelerated brain aging and Alzheimer's disease. This was a subgroup sub-analysis rather than a result in the whole group of 68 people, and the product tested was the anserine plus carnosine combination. It does not show that the supplement prevents or slows Alzheimer's disease.
Randomized, double-blind, placebo-controlled 12-week trial. 750 mg anserine + 250 mg carnosine per day (1 g total ACS) vs. placebo. Outcomes: global Clinical Dementia Rating (gloCDR), MMSE, Wechsler Memory Scale, ADAS. (Masuoka, Yoshimine, Hori, Tanaka, Asada, Abe, Nutrients)
54 subjects with mild cognitive impairment (MCI).
Score improvement in gloCDR superior in ACS group vs. placebo (p=0.023). NO beneficial effect detected on MMSE, Wechsler Memory Scale, or ADAS. Three of the four cognitive measures showed nothing. One positive result out of four, in 54 people over 12 weeks, in a group already diagnosed with mild cognitive impairment, is a weak and preliminary finding.
Double-blind, randomized, placebo-controlled trial. 60 healthy elderly volunteers (30 active, 30 placebo) received 1.0 g anserine/carnosine (3:1) for 3 months. Microarray analysis and qRT-PCR of peripheral blood mononuclear cells (PBMCs) plus WMS-LM cognitive testing. (Katakura, Totsuka, Imabayashi, Matsuda, Nutrients)
60 healthy elderly volunteers.
Decreased PBMC expression of CCL24 (inflammatory chemokine) in ACS group (p<0.05). Verbal memory (WMS-LM) preserved in ACS group. A correlation between memory scores and CCL24 suppression appeared only in the participants in their 70s, which is a subgroup analysis and cannot show cause and effect. CCL24 is a laboratory marker, not a health outcome.